182 related articles for article (PubMed ID: 11029515)
41. Efficient targeting of CD13 on cancer cells by the immunotoxin scFv13-ETA' and the bispecific scFv [13xds16].
Grieger E; Gresch G; Niesen J; Woitok M; Barth S; Fischer R; Fendel R; Stein C
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2159-2170. PubMed ID: 28669053
[TBL] [Abstract][Full Text] [Related]
42. Immunotoxins in the treatment of refractory hairy cell leukemia.
Kreitman RJ; Pastan I
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1137-51, viii. PubMed ID: 16990113
[TBL] [Abstract][Full Text] [Related]
43. Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model.
Kreitman RJ; Chang CN; Hudson DV; Queen C; Bailon P; Pastan I
Int J Cancer; 1994 Jun; 57(6):856-64. PubMed ID: 8206679
[TBL] [Abstract][Full Text] [Related]
44. Recombinant immunotoxins: protein engineering for cancer therapy.
Brinkmann U
Mol Med Today; 1996 Oct; 2(10):439-46. PubMed ID: 8897439
[TBL] [Abstract][Full Text] [Related]
45. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen.
Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H
J Immunother; 1999 Nov; 22(6):473-80. PubMed ID: 10570745
[TBL] [Abstract][Full Text] [Related]
46. B3(Fab)-PE38M: a recombinant immunotoxin in which a mutant form of Pseudomonas exotoxin is fused to the Fab fragment of monoclonal antibody B3.
Choe M; Webber KO; Pastan I
Cancer Res; 1994 Jul; 54(13):3460-7. PubMed ID: 8012967
[TBL] [Abstract][Full Text] [Related]
47. Identification of residues that stabilize the single-chain Fv of monoclonal antibodies B3.
Benhar I; Pastan I
J Biol Chem; 1995 Oct; 270(40):23373-80. PubMed ID: 7559495
[TBL] [Abstract][Full Text] [Related]
48. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins.
Wels W; Beerli R; Hellmann P; Schmidt M; Marte BM; Kornilova ES; Hekele A; Mendelsohn J; Groner B; Hynes NE
Int J Cancer; 1995 Jan; 60(1):137-44. PubMed ID: 7814146
[TBL] [Abstract][Full Text] [Related]
49. Recombinant single-chain immunotoxins against T and B cell leukemias.
Kreitman RJ; Pastan I
Leuk Lymphoma; 1994 Mar; 13(1-2):1-10. PubMed ID: 8025511
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of cell surface antigens as potential targets for recombinant tumor toxins.
Wick B; Groner B
Cancer Lett; 1997 Oct; 118(2):161-72. PubMed ID: 9459206
[TBL] [Abstract][Full Text] [Related]
51. A variant of exotoxin A that forms potent and specific chemically conjugated immunotoxins.
Chaudry GJ; Fulton RJ; Draper RK
J Biol Chem; 1993 May; 268(13):9437-41. PubMed ID: 8486636
[TBL] [Abstract][Full Text] [Related]
52. A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells.
Schwenkert M; Birkholz K; Schwemmlein M; Kellner C; Kügler M; Peipp M; Nettelbeck DM; Schuler-Thurner B; Schaft N; Dörrie J; Ferrone S; Kämpgen E; Fey GH
Melanoma Res; 2008 Apr; 18(2):73-84. PubMed ID: 18337643
[TBL] [Abstract][Full Text] [Related]
53. A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model.
Gattenlöhner S; Jörissen H; Huhn M; Vincent A; Beeson D; Tzartos S; Mamalaki A; Etschmann B; Muller-Hermelink HK; Koscielniak E; Barth S; Marx A
J Biomed Biotechnol; 2010; 2010():187621. PubMed ID: 20204062
[TBL] [Abstract][Full Text] [Related]
54. Construction, expression, and characterization of an anti-tumor immunotoxin containing the human anti-c-Met single-chain antibody and PE38KDEL.
Liu Z; Feng Z; Zhu X; Xu W; Zhu J; Zhang X; Fan Z; Ji G
Immunol Lett; 2013 Jan; 149(1-2):30-40. PubMed ID: 23026237
[TBL] [Abstract][Full Text] [Related]
55. Recombinant immunotoxins: new therapeutic agents for cancer treatment.
Pastan IH
Cancer Detect Prev; 1993; 17(2):289-93. PubMed ID: 8402714
[TBL] [Abstract][Full Text] [Related]
56. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin.
Reiter Y; Kreitman RJ; Brinkmann U; Pastan I
Int J Cancer; 1994 Jul; 58(1):142-9. PubMed ID: 8014011
[TBL] [Abstract][Full Text] [Related]
57. Immunogenicity of therapeutic recombinant immunotoxins.
Mazor R; Onda M; Pastan I
Immunol Rev; 2016 Mar; 270(1):152-64. PubMed ID: 26864110
[TBL] [Abstract][Full Text] [Related]
58. Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia.
Kreitman RJ; Chaudhary VK; Kozak RW; FitzGerald DJ; Waldman TA; Pastan I
Blood; 1992 Nov; 80(9):2344-52. PubMed ID: 1421405
[TBL] [Abstract][Full Text] [Related]
59. Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions.
Reiter Y; Brinkmann U; Kreitman RJ; Jung SH; Lee B; Pastan I
Biochemistry; 1994 May; 33(18):5451-9. PubMed ID: 7910034
[TBL] [Abstract][Full Text] [Related]
60. Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential.
Yu Y; Li J; Zhu X; Tang X; Bao Y; Sun X; Huang Y; Tian F; Liu X; Yang L
Int J Nanomedicine; 2017; 12():1969-1983. PubMed ID: 28331319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]